Association Between MASLD and Increased Risk of Serious Bacterial Infections Requiring Hospital Admission: Its Early Days DOI Open Access
Zeyu Wang, Dong Wan, Mei‐Dong Xu

и другие.

Liver International, Год журнала: 2024, Номер 45(1)

Опубликована: Дек. 17, 2024

We would like to acknowledge the contribution of meta-analysis conducted by Mantovani et al. [1], which substantiates significant association between dysfunction-associated steatotic liver disease (MASLD) and an elevated risk serious bacterial infections necessitating hospital admission. With shifts in lifestyle dietary patterns, MASLD has emerged as predominant disease, imposing a substantial social economic burden globally [2]. MAFLD extends beyond hepatic implications, exhibiting close associations with cardiovascular, renal, orthopaedic, endocrine oncological systems [3]. The infection remains insufficiently explored existing literature. This article presents rigorous investigation sample size is pioneering performing examine correlation severe infections. By synthesising data from eight studies, encompassing approximately 26 million individuals, study elucidates relationship findings have generated considerable interest warrant further inquiry. Nevertheless, following points require in-depth exploration. Firstly, figure 1, author combined analyses cross-sectional case–control studies within meta-analysis, could introduce potential bias into results. Secondly, incorporated this (references 18–21), notable age disparity exists group non-MASLD group, older patients higher propensity for developing comparison their younger counterparts [4, 5]. Consequently, variability baseline may substantially influence outcomes analysis. Finally, some included analysis contain duplicate patient data, such those 21 22), both derived Swedish Nationwide population-based cohort overlapping follow-up periods (1969 2017 vs. 1987 2020). overlap contradicts principles literature inclusion meta-analyses affect strongly concur author's article. Given that these factors above might results, we enumerate them reference readers. In conclusion, has, first time, elucidated infections, thereby enhancing awareness risks linked among researchers. Nonetheless, large-sample, multi-centre long-term are necessary substantiate findings. Z.W., D.W., M.X., Y.J. contributed preparation paper. read agreed published version manuscript. all authors' hard work. authors declare no conflicts interest. Data sharing not applicable datasets were or analysed during current study.

Язык: Английский

Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease DOI Creative Commons
Zobair M. Younossi,

Markos Kalligeros,

Linda Henry

и другие.

Clinical and Molecular Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Авг. 19, 2024

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does prevalence metabolic dysfunction associated steatotic liver disease (MASLD). Currently, 38% all adults 7-14% children adolescents have MASLD. By 2040, MASLD rate for is projected over 55%. Although many with will not develop progressive disease, given vast number patients MASLD, it has now become top indication transplant in United States those hepatocellular carcinoma (HCC) women. However, most common cause mortality among remains death cardiovascular diseases. In addition outcomes (cirrhosis HCC), increased risk developing de-novo T2D, chronic kidney sarcopenia extrahepatic cancers. Furthermore, decreased health related quality life, work productivity, fatigue healthcare resource utilization substantial economic burden. Similar other lifestyle interventions heathy diet physical activity remain cornerstone managing these patients. a T2D drugs are available treat co-morbid Resmetirom only MASH-targeted medication that was recently approved by Federal Drug Administration use stage 2-3 fibrosis. The following review provides an overview epidemiology, its factors demonstrates without further global initiatives, may increase.

Язык: Английский

Процитировано

64
Association of pan-immune-inflammatory value with metabolic dysfunction-associated steatotic liver disease: findings from NHANES 2017–2020 DOI Creative Commons
Lian-Zhen Huang,

Zi-Wei Ni,

Qi Yao

и другие.

BMC Gastroenterology, Год журнала: 2025, Номер 25(1)

Опубликована: Янв. 3, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic worldwide. The pan-immune-inflammation value (PIV) been proposed as a biomarker for assessing immune status and inflammation. There is currently no evidence regarding effect of PIV on risk MASLD. This study aimed to investigate association between cross-sectional included 6462 adults aged ≥ 20 years from National Health Nutrition Examination Survey 2017–2020. was calculated based blood count data. Weighted multivariable logistic regression employed calculate odds ratio (OR) 95% confidence interval (CI) Restricted cubic spline (RCS) analysis conducted explore dose-response relationship Stratified sensitivity analyses were performed confirm robustness our findings. Among participants, 2458 diagnosed with Positive associations LnPIV MASLD observed in all three models (Model 1: OR = 1.46, CI: 1.28–1.66, P < 0.001; Model 2: 1.41, 1.24–1.60, 3: 1.39, 1.16–1.65, 0.004). When classified into quartiles, both Q3 Q4 exhibited significantly increased risks compared reference Q1 full adjusted 3 (Q3: 1.63, 1.20–2.22, 0.012; Q4: 1.76, 1.28–2.41, 0.008; trend 0.002). RCS did not show nonlinear (P 0.093 nonlinearity). showed consistent positive subgroups, supported reliability these results. Higher levels are associated an prevalence MASLD, indicating that potentially effective inflammatory marker participants.

Язык: Английский

Процитировано

1
Metabolic dysfunction-associated steatotic liver disease: A sexually dimorphic disease and breast and gynecological cancer DOI
Xinrong Zhang,

Mindie H. Nguyen

Metabolism, Год журнала: 2025, Номер unknown, С. 156190 - 156190

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

1
Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur DOI
Stergios A. Pοlyzos,

Christos S. Mantzoros

Metabolism, Год журнала: 2025, Номер unknown, С. 156253 - 156253

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

1
The association between the dietary index for gut microbiota and non-alcoholic fatty liver disease and liver fibrosis: evidence from NHANES 2017–2020 DOI Creative Commons
Ce Zheng, Zeming Qi, Rui Chen

и другие.

BMC Gastroenterology, Год журнала: 2025, Номер 25(1)

Опубликована: Март 12, 2025

Imbalance in the gut microbiota is a key factor pathogenesis of non-alcoholic fatty liver disease (NAFLD) and fibrosis. The Dietary Index for Gut Microbiota (DI-GM) integrates potential relationship between diet diversity. This study aims to investigate association DI-GM risk NAFLD fibrosis, providing theoretical support dietary intervention strategies. utilized data from NHANES 2017–2020, including 6,181 eligible adult participants. fibrosis was assessed using quartiles, multivariate logistic regression, restricted cubic spline (RCS) analysis. Subgroup analysis performed explore predictive role different populations. All analyses were weighted ensure representativeness results. negatively associated with risks As scores increased, significantly decreased (52.81%, 43.16%, 40.40%, 31.98%, p < 0.05; 17.52%, 9.04%, 7.21%, 6.78%, 0.05). Multivariate regression revealed that, unadjusted model (Model 1), each unit increase DI-GM, by 6.9% (OR = 0.931, 95% CI: 0.886–0.979, 0.001), while 15.6% 0.844, 0.757–0.941, In quartile analysis, individuals highest (Q4) had 58% lower compared those lowest (Q1) 0.42, 0.219–0.806, 0.001). results remained significant even after adjusting covariates. RCS showed that nonlinear inflection points at 2 5, indicating enhanced protective effects. reveals negative highlighting healthy patterns prevention management through modulation, basis interventions.

Язык: Английский

Процитировано

1
3D Cell Culture Models as a Platform for Studying Tumor Progression, Testing Treatment Responses, and Discovering Biomarkers DOI
Peyda Korhan, Ezgi Bağırsakçı, Yasemin Öztemur Islakoğlu

и другие.

Methods in molecular biology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
A Global Perspective on Metabolically Driven Primary Liver Cancer: Opportunities and Challenges DOI
Joseph Ahn

The American Journal of Gastroenterology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 5, 2025

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. Correspondence: Joseph C. Ahn, MD, MS. E-mail: [email protected].

Язык: Английский

Процитировано

0
Increased risk of colorectal cancer in young males with higher cardiovascular risk: A nationwide population-based cohort study DOI
Ji Hyun Song, Suyeon Choi,

Young Sun Kim

и другие.

World Journal of Gastrointestinal Oncology, Год журнала: 2025, Номер 17(3)

Опубликована: Фев. 13, 2025

BACKGROUND Although the link between cardiovascular disease (CVD) and various cancers is well-established, relationship CVD risk colorectal cancer (CRC) remains underexplored. AIM To elucidate scores CRC incidence. METHODS In this population-based cohort study, participants from 2009 National Health Checkup were followed-up until 2020. The (CV) score was calculated as sum of factors (age, family history coronary artery disease, hypertension, smoking status, high-density lipoprotein levels) with (≥ 60 mg/dL) reducing by one. primary outcome incidence newly diagnosed CRC. RESULTS Among 2526628 individuals, 30329 developed during a mean follow-up 10.1 years. Categorized CV (0, 1, 2, ≥ 3). increased higher after adjusting for covariates [(hazard ratio = 1.155, 95% confidence interval: 1.107-1.205) in 3, P < 0.001]. This association exclusively observed males, most notably younger (< 50 years) more pronounced individuals not using statins. Moreover, even without diabetes, associated an risk. CONCLUSION Increased significantly risk, especially among populations, non-statin users. Thus, males score, at age, are recommended to control their undergo individualized screening.

Язык: Английский

Процитировано

0
The burden of cancer in metabolic dysfunction-associated steatotic liver disease DOI Open Access

Bianca Florentina Pîrvu,

Diana Clenciu,

Luiza Andreea Beldie

и другие.

Romanian Journal of Morphology and Embryology, Год журнала: 2025, Номер 65(4), С. 627 - 635

Опубликована: Фев. 13, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic worldwide and has become a major public health problem. MASLD frequently progresses to cirrhosis hepatocellular carcinoma, but recent studies also show frequent association with extrahepatic cancers. One of mechanisms involved in both locations insulin resistance hyperinsulinemia. The aim this narrative review was present main etiopathogenic cancer development patients MASLD.

Язык: Английский

Процитировано

0
Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database DOI Creative Commons
Hui Du, Jihan Huang, Youhua Wang

и другие.

BMC Gastroenterology, Год журнала: 2025, Номер 25(1)

Опубликована: Март 7, 2025

With the rising incidence of MASLD, extensive drug research has been conducted in clinical trials. The study examined design principles and objectives MASLD therapeutics, order to offer guidance trial participants decision makers. By searching data registered on clinicaltrials.gov platform, 1209 interventional trials were screened. These subsequently evaluated based stage, design, intervention modalities, outcome metrics, other pertinent factors. A total 1,209 included, which 199 from 2000 2012 (16.46%) 1010 2013 2024 (83.54%), reflecting growing body MASLD. Regarding model type, single-group designs employed 232 (19.19%) trials, parallel 873(72.21%). 13 early phase 1 (1.08%), 152 (12.57%) 1, 34 (2.81%) 1/phase 2, 301 2 (24.90%), 19 (1.57%) 2/phase 3, 72 (5.96%) 84 (6.95%) 4. Within these three primary outcomes for interventions hepatic histological improvement, fat content adverse events. Furthermore, 140 with results therapeutic purposes (This accounted 88.61% 158 results) primarily aimed improve through mechanisms such as metabolic energy balance, inflammatory immunomodulatory, lipid reduction, targeting PPAR, FXR, ACC GLP-1. This suggests basic characteristics global current are mainly focused drug-related treatments, drugs inflammation metabolism still first choice studies.

Язык: Английский

Процитировано

0